Novogen Limited (NASDAQ:KZIA) Receives $25.80 Average Price Target from Brokerages

Novogen Limited (NASDAQ:KZIA) has been given a consensus rating of “Moderate Buy” by the six analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $25.80.

A number of research analysts have recently issued reports on KZIA shares. BTIG Research started coverage on Novogen in a report on Wednesday, July 1st. They set a “buy” rating and a $34.00 price target on the stock. Laidlaw initiated coverage on shares of Novogen in a report on Wednesday, April 15th. They set a “buy” rating and a $25.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Novogen in a research report on Tuesday, April 21st. Finally, Lake Street Capital assumed coverage on shares of Novogen in a report on Thursday, June 11th. They issued a “buy” rating and a $32.00 price objective on the stock.

Novogen Stock Up 4.5%

Shares of KZIA stock opened at $13.56 on Monday. The business has a 50-day moving average price of $13.21 and a two-hundred day moving average price of $9.62. Novogen has a 12-month low of $4.86 and a 12-month high of $17.40.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.